On May 20, 2021 Nippon Kayaku reported that Financial Results for the Fiscal Year Ending March 31, 2021 (FY 2021) (Press release, Nippon Kayaku, MAY 20, 2021, View Source_fiscal_ym14/100505/00.pdf" target="_blank" title="View Source_fiscal_ym14/100505/00.pdf" rel="nofollow">View Source [SID1234580346])
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
FY 2021 : Topics
(1) 4 Consolidated Results
• Net sales and profit was decreased from the previous fiscal year. But net sales and profit was increased from the forecast in January, 2021
• Sales of Functional Chemicals and Safety systems in 1st half declined due to COVID-19 pandemic, but sales in 2nd half was rapidly recovered with automobile market demand
• Catalyst of Functional Chemicals achieved 10.9 billion yen sales, record high
• Biosimilars was 10.4 billion yen sales, record high, while the drug price revisions
FY 2021 : Topics (2) Functional Chemicals Business
• Sales of epoxy resins were strong for semiconductor and circuit board due to the growth in 5G base stations and IT devices, and recovered for automobile applications from 3rd quarter
• Sales of epoxy resins for use in automobile applications were strong
• The cleaner for LCD and semiconductor industry business acquired from Henkel AG &Co. KGaA was performed well for semiconductor usage
• Teikoku Taping Systems Co., Ltd were acquired, to spread the semiconductor applications
• Sales of colorants for inkjet printers for consumer use were strong, owing to the positive impact of working from home during the COVID-19 pandemic
• Sales of colorants for inkjet printers used in industrial applications declined abruptly due to the decrease in demand for printed advertising, sales for textile dyes declined due to the clothing sales decrease, and thermal developer declined due to the decrease in demand for movie and theater ticket, but all applications slightly recovered from 3rd quarter • Sales of Catalyst achieved 10.9 billion yen sales, record high
• Polatechno Co., Ltd was made a wholly owned subsidiary, was integrated from October and proceeded the strength of the governance and integrated operations. The sales slightly recovered for automobile application from 3rd quarter
5 FY 2021 : Topics (3) Pharmaceuticals Business
• Biosimilars: Sales growth for INFLIXIMAB BS and TRASTUZUMAB BS was strong
New products: The cancer-related generic drug APREPITANT recorded strong growth The biomedicine PORTRAZZA achieved market penetration, increased its adaption Approach for the domestic manufacturing with Calitivecs Inc. Continue to focus on co-promotion of NUBEQA Tab., a therapeutic drug for prostate cancer
• Products under development: NK105 (Polymeric micelle paclitaxel) was canceled to develop for breast cancer due to Phase II clinical trial results Launch for development related bio and polymeric technology with Biomedical companies 6 FY 2021 : Topics (4) Safety Systems Business
Rapidly decline due to the stagnation of global automobile market
• Demands rapidly recovered in China from 1st quarter, in Japan and North America from 2nd quarter
Sales rapidly recovered in all regions from 3rd quarter, although there were regional differences
• Total shipment of automobile safety devices glowed to 80 million devices in 3rd quarter
• Safety equipment for drones, PARASAFE progress to develop on schedule towards the start of sales in December, 2021 Agrochemicals and Other Businesses
• Domestic sales was strong, but oversea sales declined due to the procurement difficulty of some of raw materials
• Acquired sales rights of "Teron" and "Ashahi D-D," then started of those sales from 4th quarter 7 ESG :
FY 2021 Topics 8
▸ Enlargement and Strengthened of Corporate Governance
・Increased the number of independent outside directors by one
・Established the Nomination and Remuneration Advisory Committee Members: five directors, the majority are independent outside directors (3 out of 5) Roles: strengthen the fairness, transparency and objectivity of the procedures related to the nomination and remuneration etc. of directors etc.
・Formulated our Basic Policy on Corporate Governance
・Enlargement on Corporate Governance (consider to enlargement towards the general meeting in June)
▸ Environment target FY 2031 NK groups’ GHG emission target in FY 2031 (Scope 1+2)setting at 32.5% decrease via FY 2019
▸ Further information-CSR information: View Source report: View Source _fiscal_ym17/88077/00.pdf